Our Artificial Intelligence (AI) based technology precisely identifies and matches patients clinical trials in community practices. Our proprietary technology is comprised of:
Natural Language Processing for medical records, molecular diagnostics test results and clinical trial protocols; oncology proprietary ontology with 50, 000 elements specific to detailed oncology trial pre-screening
Machine learning technology for scaled pre-screening; prescreening in the matter of seconds instead of hours
Real world data platform that generates insights for drug discovery and development; thousands of full patient longitudinal journey for rapid insights
AI powered patient identification technology; patients are found for pre-screening across the globe in the matter of seconds if they are in Massive Bio’s patient and provider network for trials
Next Generation Oncology Clinical Trials Platform
Massive Bio Controls Patient Enrollment Value Chain in Oncology
Virtual Patient Contact Center
Patients are onboarded from providers’ call centers, online marketing efforts, advocacy groups and Massive Bio’s proprietary SYNERGY-AI /registry with cutting edge technology. Specially trained patient advocates provide patient education and engagement before escalation to the case management team.
Clinical Trial Matching System (CTMS)
Patients are pre-screened with AI based technology for trials and advanced care options if trial is not available. Sub-specialist and case management support are provided for operationalization of recommendations.
Just In Time (JIT) Hub
Best sites are identified with AI based global patient identification registry, PI is onboarded, and site is activated with cutting edge technology.
Real World Insights
Patients clinical, genomic and outcomes information are captured, and synthetic control arm, biomarker discovery and off-label indication expansion studies are developed with AI based technology.
Oncology Clinical Trials Are Broken
Particularly patient access from community practices (i.e. Non-NCI designated cancer centers) where 85% of cancer patients are treated
Current state 3% Enrollment rate
Limited technology and infrastructure
Limited patient engagement
Significant operational inefficiency
Future state 20% Enrollment rate
End-to-end technology platform
Virtual infrastructure as applicable
Stakeholder orchestrator Massive Bio
Becker's Hospital Review, 2019
100+ artificial intelligence companies know in healthcare
Thrive Global, 2018
CEO selected 99 "Limit Breaking Female Founders"
Philadelphia Inquirer, 2019
CMO selected "Influencer in Healthcare" in the category of Outstanding Healthcare Provider
CEO selected Digital Health Pioneer
We’re Here To Help
For close to 10,000 patients that have reached out to our patient contact center
of the patients are eligible at least one trial
of the patients are enrolled